The cardiometabolic pipeline leverages RNAi technology to address both rare and prevalent lipid disorders, with key programs in severe hypertriglyceridemia and HoFH advancing toward pivotal data and regulatory milestones. Dual-targeting siRNA innovation aims to address mixed hyperlipidemia and residual ASCVD risk, with multiple launches and first-in-human data expected in the next 12–18 months.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.